Cibinqo is a medicine used to treat moderate to severe eczema that hasn't gotten better with other treatments. It is taken as a pill by mouth. It works by calming parts of the immune system that cause itchy, inflamed skin.
Every report comes from a Lived member, sent anonymously.
Have you tried Cibinqo (Abrocitinib) for Eczema?
Abrocitinib, sold as Cibinqo, is a prescription pill for moderate to severe atopic dermatitis, the most common form of eczema, in adults and children 12 and older. In the US it is approved for eczema that other medicines taken by mouth or injection, including biologics such as Dupixent (dupilumab), have not controlled, or for people who cannot use those treatments. It belongs to a group of medicines called Janus kinase (JAK) inhibitors, which calm parts of the immune system throughout the body rather than only in the skin. The American Academy of Dermatology counts abrocitinib among the systemic treatments it strongly recommends for adults whose eczema is not controlled by creams and ointments, although the US label places it after other systemic options. It is not meant to be combined with other JAK inhibitors, biologics or medicines that suppress the immune system.
In atopic dermatitis, the immune system in the skin is overactive. Signaling proteins called cytokines, including interleukin-4, interleukin-13 and interleukin-31, drive the inflammation, the weakened skin barrier and much of the itch. Many of these signals reach the inside of cells through enzymes called Janus kinases, or JAKs. Abrocitinib blocks JAK1, one member of this family, which turns down those eczema-driving signals. Blood markers of inflammation fall during treatment and drift back toward their earlier levels within about four weeks of stopping. The same immune dampening that quiets eczema also makes the body less able to fight some infections, which is why safety checks are part of treatment. Researchers have not fully worked out which effects of JAK blocking produce the benefit.
Abrocitinib is a tablet taken once a day, at about the same time each day, with or without food. The usual starting dose is 100 mg. If eczema has not improved enough, the prescriber may raise it to 200 mg, which produced stronger and faster responses in trials but also more nausea, acne and drops in platelet count. A 50 mg dose is used for people with moderate kidney disease, people whose bodies clear the drug slowly because of an inherited difference in a liver enzyme called CYP2C19, and people taking certain medicines that block that enzyme. It is not recommended for severe kidney disease or severe liver disease. Swallow the tablets whole with water; do not crush, split or chew them. If a dose is missed, take it as soon as possible, unless the next dose is less than 12 hours away, in which case skip it. Abrocitinib can be used alone or alongside prescribed steroid creams or ointments. Before the first dose, the prescriber checks for tuberculosis (TB) and hepatitis B and C, orders a complete blood count, and brings vaccinations up to date, including the shingles vaccine.
Nausea is the most common side effect, especially at 200 mg, where about one in seven people in the trials had it, compared with about one in 50 on placebo. Headache, cold-like symptoms, acne, dizziness, vomiting, stomach discomfort and cold sores (herpes simplex) were also more frequent than on placebo, and acne and nausea in particular rise with the dose. Because abrocitinib dampens immune defenses, infections are the main serious concern. The infections most often serious in trials were herpes simplex, shingles (herpes zoster) and pneumonia, and shingles was about twice as common in people 65 and older. Call the prescriber right away for signs of infection, such as fever, chills or sweats, a new cough, warm, red or painful skin, burning when urinating, or a painful blistering rash. Treatment may be paused until the infection is under control. Blood tests can show lower platelets (cells that help blood clot) or lower lymphocytes (infection-fighting white blood cells), as well as higher cholesterol; these usually cause no symptoms and are found through monitoring. Retinal detachment, a separation of the light-sensing layer at the back of the eye, has been reported, so report any sudden change in vision to the prescriber right away.
Abrocitinib carries a boxed warning from the US Food and Drug Administration (FDA), the agency's most prominent caution. Besides serious infections, it covers heart attack, stroke, blood clots, certain cancers including lymphoma and lung cancer, and a higher rate of death. Much of this comes from a large study of a different JAK inhibitor in people 50 and older with rheumatoid arthritis and at least one heart disease risk factor, compared with tumor necrosis factor (TNF) blockers (another type of anti-inflammatory medicine). Heart events, blood clots and cancers have also occurred in people taking abrocitinib for eczema. Current or past smokers and people with other heart risk factors face more risk, which is part of weighing whether the medicine is a good fit. Skin cancers can also occur, so skin checks, sun protection and avoiding tanning beds are advised. Get emergency help for symptoms of a heart attack or stroke, such as chest pressure or pain lasting more than a few minutes, weakness on one side of the body or slurred speech. Stop the medicine and get medical help right away for signs of a blood clot: swelling, pain or tenderness in a leg, sudden unexplained chest or upper back pain, or shortness of breath. During the first three months, abrocitinib must not be taken with antiplatelet medicines (blood thinners that work on platelets), apart from low-dose aspirin of 81 mg or less a day, because platelet counts can fall and bleeding risk rises. Some other medicines change how the liver handles abrocitinib, so some call for a lower dose and others should be avoided; give the prescriber and pharmacist a full list, including over-the-counter products and supplements. Live vaccines should be avoided just before, during and just after treatment. People with diabetes may need to check blood sugar more often, since low blood sugar has been reported after starting JAK inhibitors. There are too few pregnancy data to know the risk, and a pregnancy registry collects outcomes. Breastfeeding is not advised during treatment and for one day after the last dose. Animal studies suggest abrocitinib may reduce female fertility.
Itch often eases quickly. In trials, a large drop in itch within two weeks was seen in about a quarter of people on 200 mg and about one in ten on 100 mg, compared with very few on placebo. By 12 weeks, about six in ten people on 200 mg and four in ten on 100 mg had their eczema severity score improve by at least 75%, compared with about one in ten on placebo. In head-to-head trials, the 200 mg dose relieved itch faster than dupilumab in the first weeks, while most results at 16 weeks were similar. Not everyone responds, and the prescriber will review progress after several weeks to decide whether to adjust the dose or change treatment. Follow-up includes a blood count about four weeks after starting and again four weeks after any dose increase, and a cholesterol check at around four weeks. Abrocitinib controls eczema rather than curing it. In a trial where people who had responded were switched to placebo, about four in five had a flare within 40 weeks, compared with about one in five who stayed on 200 mg; restarting treatment brought many back under control. How long to continue is a decision made with the prescriber, weighing eczema control against long-term risks.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Cibinqo (Abrocitinib), what you've noticed, or ask the community a question.